Atwater Malick’s AbbVie ABBV Stock Holding History

Atwater Malick’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$841K	Buy	3,342 +315	+10%	+$67.8K	0.18%	61
2026 Q1	$658K	Sell	3,027 -210	-6%	-$46.6K	0.18%	51
2025 Q4	$740K	Buy	3,237 +391	+14%	+$89.1K	0.2%	45
2025 Q3	$659K	Hold	2,846	–	–	0.19%	48
2025 Q2	$528K	Buy	2,846 +135	+5%	+$25.1K	0.17%	54
2025 Q1	$568K	Sell	2,711 -13	-0.5%	-$2.53K	0.19%	50
2024 Q4	$484K	Hold	2,724	–	–	0.16%	49
2024 Q3	$538K	Sell	2,724 -40	-1%	-$7.46K	0.17%	51
2024 Q2	$474K	Hold	2,764	–	–	0.16%	53
2024 Q1	$503K	Buy	2,764 +1,095	+66%	+$189K	0.18%	56
2023 Q4	$259K	Sell	1,669 -468	-22%	-$68.2K	0.1%	62
2023 Q3	$319K	Hold	2,137	–	–	0.14%	55
2023 Q2	$288K	Buy	2,137 +510	+31%	+$74.8K	0.12%	59
2023 Q1	$259K	Buy	1,627 +24	+1%	+$3.67K	0.12%	55
2022 Q4	$259K	Buy	+1,603	New	+$246K	0.13%	51
2019 Q4	–	Sell	-686	Closed	-$52K	–	39
2019 Q3	$52K	Buy	+686	New	+$47K	0.04%	74

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Atwater Malick's ABBV Position: Q2 2026 in Review

Atwater Malick increased its AbbVie (ABBV) stake by 10% in Q2 2026, buying an estimated $67.8K and bringing the position to 3,342 shares worth $841K. The position accounts for 0.18% of the portfolio, ranked #61.

Atwater Malick first reported a position in ABBV in Q3 2019 and has held it in 16 quarters since. 4,215 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Atwater Malick held 3,342 shares of AbbVie worth $841K as of Q2 2026.
Atwater Malick bought 315 AbbVie shares in Q2 2026, an estimated $67.8K.
AbbVie made up 0.18% of Atwater Malick's portfolio in Q2 2026, its #61 holding.
Atwater Malick first reported a position in AbbVie in Q3 2019 and has held it in 16 quarters since.
4,215 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Atwater Malick's 13F filing for Q2 2026, filed 27 Jul 2026.